October 5, 2015New England Journal of MedicineOpen Access

Reduced Leaflet Motion in Bioprosthetic Aortic Valves — The FDA Perspective

View Full Paper

Ask AI

Bookmark

Key result

Reduced leaflet motion in bioprosthetic aortic valves requires further investigation to determine if it is a clinically meaningful risk or merely an advanced-imaging phenomenon.

Design

Editorial

Authors

JLJohn C. LaschingerUnited States Food and Drug Administration CWChangfu WuInterventional / Structural Cardiology NINicole G. IbrahimCenter for Devices and Radiological Health

Discussion

Member takes

Implication

The clinical significance and risks of reduced leaflet motion in bioprosthetic aortic valves remain unclear and require further investigation according to the FDA.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Laschinger et al. (2015) studied this question. Reduced leaflet motion in bioprosthetic aortic valves requires further investigation to determine if it is a clinically meaningful risk or merely an advanced-imaging phenomenon.

synapsesocial.com/papers/6aa1ff8d1b85e0eabc07e7dc https://doi.org/10.1056/nejmp1512264

Topics

Valvular heart disease

View Full Paper

Ask AI

Bookmark

Implication

The clinical significance and risks of reduced leaflet motion in bioprosthetic aortic valves remain unclear and require further investigation according to the FDA.

Reduced Leaflet Motion in Bioprosthetic Aortic Valves — The FDA Perspective

Discussion

Member takes

Implication

Key Points

Cite This Study

Topics

Reduced Leaflet Motion in Bioprosthetic Aortic Valves — The FDA Perspective

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Topics

Also Consider